Technical Analysis for XRTX - Xortx Therapeutics Inc

Grade Last Price % Change Price Change
D 4.500 5.63% 0.240
XRTX closed down 5.33 percent on Tuesday, April 16, 2024, on 12 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 5.63%
Stochastic Reached Oversold Weakness 5.63%
Wide Bands Range Expansion 5.63%
Down 3 Days in a Row Weakness 5.63%
Down 4 Days in a Row Weakness 5.63%
Gapped Down Weakness 5.63%
Oversold Stochastic Weakness 5.63%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%

   Recent Intraday Alerts

Alert Time
Rose Above Previous Day's High about 1 hour ago
Up 5% about 1 hour ago
Up 3% about 1 hour ago
Up 2% about 1 hour ago
Up 1% about 1 hour ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Xortx Therapeutics Inc Description

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medical Specialties Diabetes Organ Systems Infection Hypertension Kidney Disease

Is XRTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.35
52 Week Low 0.33
Average Volume 18,905
200-Day Moving Average 2.403
50-Day Moving Average 4.767
20-Day Moving Average 5.114
10-Day Moving Average 4.775
Average True Range 0.473
RSI (14) 41.18
ADX 20.38
+DI 22.011
-DI 34.556
Chandelier Exit (Long, 3 ATRs) 6.181
Chandelier Exit (Short, 3 ATRs) 5.629
Upper Bollinger Bands 6.350
Lower Bollinger Band 3.878
Percent B (%b) 0.15
BandWidth 48.326
MACD Line -0.165
MACD Signal Line -0.038
MACD Histogram -0.1269
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.335
Resistance 3 (R3) 4.340 4.320 4.323
Resistance 2 (R2) 4.320 4.301 4.318 4.318
Resistance 1 (R1) 4.290 4.289 4.280 4.285 4.314
Pivot Point 4.270 4.270 4.265 4.268 4.270
Support 1 (S1) 4.240 4.251 4.230 4.235 4.206
Support 2 (S2) 4.220 4.239 4.218 4.202
Support 3 (S3) 4.190 4.220 4.198
Support 4 (S4) 4.185